

Sushil Kumar

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/10397065/sushil-kumar-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

22
papers

1,354
citations

11
h-index

25
g-index

25
ext. papers

1,819
ext. citations

7.2
avg, IF

4.46
L-index

#	Paper	IF	Citations
22	Microenvironmental Regulation of Macrophage Transcriptomic and Metabolomic Profiles in Pulmonary Hypertension. <i>Frontiers in Immunology</i> , 2021 , 12, 640718	8.4	3
21	Discovery, synthesis and biological characterization of a series of -(1-(1,1-dioxidotetrahydrothiophen-3-yl)-3-methyl-1-pyrazol-5-yl)acetamide ethers as novel GIRK1/2 potassium channel activators. <i>RSC Medicinal Chemistry</i> , 2021 , 12, 1366-1373	3.5	
20	Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis. <i>Oncotarget</i> , 2021 , 12, 1470-1489	3.3	6
19	The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy. <i>Cancers</i> , 2021 , 13,	6.6	1
18	Synthesis and SAR Studies of 1-Pyrrolo[2,3-]pyridine-2-carboxamides as Phosphodiesterase 4B (PDE4B) Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2020 , 11, 1848-1854	4.3	5
17	KVA-D-88, a Novel Preferable Phosphodiesterase 4B Inhibitor, Decreases Cocaine-Mediated Reward Properties. <i>ACS Chemical Neuroscience</i> , 2020 , 11, 2231-2242	5.7	2
16	Immunoglobulin-driven Complement Activation Regulates Proinflammatory Remodeling in Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 201, 224-239	10.2	34
15	Human bronchial carcinoid tumor initiating cells are targeted by the combination of acetazolamide and sulforaphane. <i>BMC Cancer</i> , 2019 , 19, 864	4.8	7
14	Discovery, synthesis and characterization of a series of (1-alkyl-3-methyl-1H-pyrazol-5-yl)-2-(5-aryl-2H-tetrazol-2-yl)acetamides as novel GIRK1/2 potassium channel activators. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019 , 29, 791-796	2.9	3
13	The role of Sulforaphane in cancer chemoprevention and health benefits: a mini-review. <i>Journal of Cell Communication and Signaling</i> , 2018 , 12, 91-101	5.2	69
12	Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models. <i>Translational Oncology</i> , 2018 , 11, 911-919	4.9	9
11	Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma. <i>BMC Cancer</i> , 2017 , 17, 156	4.8	24
10	Metabolic and Proliferative State of Vascular Adventitial Fibroblasts in Pulmonary Hypertension Is Regulated Through a MicroRNA-124/PTBP1 (Polypyrimidine Tract Binding Protein 1)/Pyruvate Kinase Muscle Axis. <i>Circulation</i> , 2017 , 136, 2468-2485	16.7	100
9	Combination therapy in combating cancer. <i>Oncotarget</i> , 2017 , 8, 38022-38043	3.3	818
8	Metabolic Reprogramming Regulates the Proliferative and Inflammatory Phenotype of Adventitial Fibroblasts in Pulmonary Hypertension Through the Transcriptional Corepressor C-Terminal Binding Protein-1. <i>Circulation</i> , 2016 , 134, 1105-1121	16.7	73
7	Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models. <i>Clinical Cancer Research</i> , 2016 , 22, 2697-708	12.9	23
6	Metronomic Chemotherapy in Pediatric Malignancies 2014 , 157-172		

5	Tumor dynamics in response to antiangiogenic therapy with oral metronomic topotecan and pazopanib in neuroblastoma xenografts. <i>Translational Oncology</i> , 2013 , 6, 493-503	4.9	21
4	Combination of carbonic anhydrase inhibitor, acetazolamide, and sulforaphane, reduces the viability and growth of bronchial carcinoid cell lines. <i>BMC Cancer</i> , 2013 , 13, 378	4.8	42
3	Nab-paclitaxel is an active drug in preclinical model of pediatric solid tumors. <i>Clinical Cancer Research</i> , 2013 , 19, 5972-83	12.9	42
2	Preclinical models for pediatric solid tumor drug discovery: current trends, challenges and the scopes for improvement. <i>Expert Opinion on Drug Discovery</i> , 2012 , 7, 1093-106	6.2	4
1	Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. <i>Clinical Cancer Research</i> , 2011 , 17, 5656-67	12.9	64